Drug Profile


Alternative Names: CS-8958; Inavir; LANI; Laninamivir octanoate; Laninamivir octanoate hydrate; R-118958

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Aviragen Therapeutics; Daiichi Sankyo Company
  • Class Antivirals; Guanidines; Small molecules
  • Mechanism of Action Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 02 Feb 2017 Daiichi Sankyo initiates phase III trial for Influenza infections (nebuliser formulation) in Japan before February 2017 (Daiichi Sankyo pipeline, February 2017)
  • 15 Dec 2016 Biomarkers information updated
  • 06 Oct 2016 Daiichi Sankyo plans a phase III trial Influenza virus infections (In children, In adolescents, In adults, In the elderly) in Japan (Inhalation) (JapicCTI-163397)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top